GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis

Summary

The aim of this double blind, placebo controlled, study is to evaluate activity consistent with efficacy provided by 14 days administration of GI270384X, and to provide preliminary pharmacokinetics and safety/tolerability of 14 days administration of GI270384X in patients with mild to moderate active ulcerative colitis (UC).

Timeline

Start

2004-12

Primary completion

—

Completion

—

Drugs

Indications